CHA AI Healthkare차AI헬스케어

CHA AI Healthkare is loss-making at the operating line, but its trailing net income is positive, so the headline profit figure needs careful reading.

The company, which sells cosmetics and mask packs (partly under OEM arrangements), reported trailing twelve-month revenue of about ₩8.4B to H1 2026 and an operating loss of about ₩7.6B. Its trailing net income of about ₩8.1B is positive despite the operating loss, and the data does not explain what drove that gap. Shares closed at ₩5,060 with a market cap of about ₩92B, down about 63% over one year.

What stands out

• Trailing operating margin is -90.6%, and the operating loss has persisted in every year from 2021 to 2025 in the data provided.
• Revenue fell 53.4% in 2025 to about ₩7.3B, and trailing revenue to H1 2026 is about ₩8.4B.
• Trailing net income of ₩8.1B and an ROE of 14.7% sit awkwardly against the operating loss; the data does not break down the non-operating items behind this.
• Trailing free cash flow is about -₩6.1B, and borrowings of about ₩40B are well above cash of about ₩10.9B.
• Filings in the last few months include a half-year report, several shareholding reports, a major sales or supply contract (June 2026) and a rights offering or equity-linked bond result (June 2026). The data includes no news headlines.

What to watch

• The next half-year or annual results, to see whether the operating loss narrows and whether the trailing net income is repeated.
• Debt levels and cash burn, given borrowings of about ₩40B against about ₩10.9B of cash and negative free cash flow.
• Follow-up on the June 2026 supply contract and the equity-linked financing, since the data does not give their size or terms.